CAJ | 학술논문

目的：评价卡培他滨维持治疗对联合化疗有效的复发转移三阴乳腺癌的疗效和安全性。方法选择浸润性乳腺癌激素受体雌激素受体(ER)、孕激素受体(PR)及人类表皮生长因子受体2(HER2)均为阴性,病灶为不可切除的局部晚期或已经转移的女性患者46例,分为治疗组(n=23)和对照组(n=23),治疗组行联合方案化疗6个疗程有效后口服卡培他滨维持治疗,对照组单纯行联合方案化疗6个疗程,比较两组疗效和不良反应。结果治疗组的部分缓解(PR)、病情进展(PD)、临床有效率(RR)及疾病控制率(DCR)率明显优于对照组,差异有统计学意义(P <0.05)。两组比较,除了治疗组出现手足综合征之外,其他不良反应差异无统计学意义(P >0.05)。结论卡培他滨维持治疗对联合化疗有效的复发转移三阴乳腺癌效果好,可提高晚期乳腺癌的有效率、DCR,近期疗效。
목적：평개잡배타빈유지치료대연합화료유효적복발전이삼음유선암적료효화안전성。방법선택침윤성유선암격소수체자격소수체(ER)、잉격소수체(PR)급인류표피생장인자수체2(HER2)균위음성,병조위불가절제적국부만기혹이경전이적녀성환자46례,분위치료조(n=23)화대조조(n=23),치료조행연합방안화료6개료정유효후구복잡배타빈유지치료,대조조단순행연합방안화료6개료정,비교량조료효화불량반응。결과치료조적부분완해(PR)、병정진전(PD)、림상유효솔(RR)급질병공제솔(DCR)솔명현우우대조조,차이유통계학의의(P <0.05)。량조비교,제료치료조출현수족종합정지외,기타불량반응차이무통계학의의(P >0.05)。결론잡배타빈유지치료대연합화료유효적복발전이삼음유선암효과호,가제고만기유선암적유효솔、DCR,근기료효。
Objective To evaluate the clinical efficacy and safety of capecitabine continuous maintenance in treatment of re-currence of triple-negative breast cancer,which had responded to combined chemoradiotherapy.Methods The triple-negative breast cancer was defined as negative of ER,PR and HER2.A total of 46 patients of triple-negative breast cancer were divided into the treatment group (23 patients)and the control group (23 patients).The treatment group was given capecitabine continuous mainte-nance after 6 cycles of chemotherapy.The control group was given 6 cycles of combined chemotherapy only.The clinical efficacy and safety was evaluated between the two groups.Results The PR,PD,RR,and DCR in the treatment group were significantly higher than those in the control group(P <0.05).The acute toxic effects (except for hand-foot syndrome)were similar in two group(P >0.05).Conclusion Capecitabine continuous maintenance after combined chemoradiotherapy in treatment of recurrence of triple-neg-ative breast cancer is more effective,lower toxicity and tolerable.